Meng Tingwei, Pan Qingqing, Luo Yaping
Department of Nuclear Medicine, State Key Laboratory of Common Mechanism Research for Major Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College Hospital, Beijing, China.
Hell J Nucl Med. 2025 May-Aug;28(2):124-130. doi: 10.1967/s002449912803. Epub 2025 Aug 4.
Gallium-68 (Ga)-pentixafor, a novel positron emission tomography (PET) tracer with high affinity for C-X-C motif chemokine receptor 4 (CXCR4), has recently been introduced in order to assess the CXCR4 expression status in vivo. This study is to investigate the role of Ga-pentixafor in detecting various tumors with mice models and to provide references to clinical studies.
Gallium-68-pentixafor and fluorine-18-fluorodeoxyglucose (F-FDG) PET was performed in opm-2 (lymphoma), daudi (myeloma) and panc1 (pancreatic cancer)-bearing mice. Tumor and background tissue uptake between Ga-pentixafor and F-FDG PET were compared. Gallium-68-pentixafor PET/computed tomography (CT) was performed in four patients with lymphoma and three patients with multiple myeloma, and F-FDG PET/CT was performed as a reference.
The uptake of Ga-pentixafor in background tissues including muscle, liver and kidneys were all lower than those of F-FDG. The uptake of Ga-pentixafor in the tumors of lymphoma and myeloma-bearing xenografts was comparable or higher than those of F-FDG. However, the tumors of panc-1 xenografts had much lower uptake of Ga-pentixafor than those in lymphoma and myeloma-bearing mice, and it was also significantly lower than those of F-FDG. The high uptake of Ga-pentixafor in vivo was confirmed by the high expression of CXCR4 in tumors with immunochemical analysis. Gallium-68-pentixafor PET/CT in patients with marginal zone lymphoma (MZL) and myeloma showed more intense uptake and more extensive involvement than F-FDG PET/CT did. Gallium-68-pentixafor and F-FDG PET/CT showed comparable uptake in the patient with follicular lymphoma.
Gallium-68-pentixafor is a promising agent for the evaluation of lymphoproliferative diseases.
镓-68（Ga）-喷替沙氟是一种对C-X-C基序趋化因子受体4（CXCR4）具有高亲和力的新型正电子发射断层扫描（PET）示踪剂，最近已被引入用于评估体内CXCR4的表达状态。本研究旨在探讨Ga-喷替沙氟在小鼠模型中检测各种肿瘤的作用，并为临床研究提供参考。
对荷opm-2（淋巴瘤）、daudi（骨髓瘤）和panc1（胰腺癌）小鼠进行镓-68-喷替沙氟和氟-18-氟脱氧葡萄糖（F-FDG）PET检查。比较Ga-喷替沙氟和F-FDG PET之间肿瘤和背景组织的摄取情况。对4例淋巴瘤患者和3例多发性骨髓瘤患者进行镓-68-喷替沙氟PET/计算机断层扫描（CT），并以F-FDG PET/CT作为对照。
Ga-喷替沙氟在包括肌肉、肝脏和肾脏在内的背景组织中的摄取均低于F-FDG。Ga-喷替沙氟在荷淋巴瘤和骨髓瘤异种移植瘤中的摄取与F-FDG相当或更高。然而，panc-1异种移植瘤对Ga-喷替沙氟的摄取远低于荷淋巴瘤和骨髓瘤小鼠，且也显著低于F-FDG。免疫化学分析证实肿瘤中CXCR4的高表达证实了Ga-喷替沙氟在体内的高摄取。边缘区淋巴瘤（MZL）和骨髓瘤患者的镓-68-喷替沙氟PET/CT显示比F-FDG PET/CT摄取更强烈且累及范围更广。滤泡性淋巴瘤患者的镓-68-喷替沙氟和F-FDG PET/CT显示摄取相当。
镓-68-喷替沙氟是一种有前途的用于评估淋巴增殖性疾病的药物。
